Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders - Weighted-Average Common Stock Equivalents were Excluded From Calculation of Diluted Net Loss Per Share (Details) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities	19,977,348	13,696,497	18,856,587	13,788,980
Common Stock Options Granted
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities	13,996,403	12,901,028	13,984,427	13,205,328
Nonvested Restricted Stock Units Outstanding
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities	5,486,711	795,469	4,490,170	572,194
Nonvested Market-based Restricted Stock Units Outstanding Granted
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities	494,234		381,990
Common Stock Warrant Outstanding
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities				11,458